Substance / Medication

Bivalirudin

Overview

Active Ingredient
bivalirudin
RxNorm CUI
60819

Indications

Bivalirudin for injection is indicated for use as an anticoagulant for use in patients undergoing percutaneous coronary intervention (PCI) including patients with heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis syndrome.

Labeler: Civica, Inc.Updated: 2025-09-10T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

Bivalirudin is contraindicated in patients with: • Active major bleeding; • [see Adverse Reactions (6.1) ] Hypersensitivity (e.g., anaphylaxis) to bivalirudin or its components.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Bivalirudin Versus Heparin in Patients Undergoing Percutaneous Coronary Intervention in Acute Coronary Syndromes.
Krittanawong Chayakrit, Ahuja Tania, Wang Zhen et al. · Crit Pathw Cardiol · 2025
PMID: 39133562Meta-Analysis
Meta-Analysis Comparing Bivalirudin Versus. Unfractionated Heparin in Adult Patients With Extracorporeal Membrane Oxygenation.
Kido Kazuhiko, Kabulski Galen M, Szymanski Thomas W et al. · J Pharm Pract · 2024
PMID: 36449392Meta-Analysis
Heparin and Bivalirudin in Percutaneous Coronary Intervention for Acute Coronary Syndromes: A Review Article.
Wang Guiping, Qi Kaijie, Li Xuyang et al. · Cardiovasc Ther · 2024
PMID: 39749045Meta-AnalysisFull text (PMC)
Differential Use of Glycoprotein IIb/IIIa Inhibitors with Bivalirudin in Patients with STEMI Undergoing PCI: A Systematic Review and Meta-Analysis.
Mushahid Hasan, Shah Syeda Ayesha, Farhan Syed Husain et al. · Am J Cardiovasc Drugs · 2024
PMID: 38683263Meta-Analysis

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Bivalirudin (substance)
SNOMED CT
129498009
UMLS CUI
C0168273
RxNorm CUI
60819
Labeler
Civica, Inc.

Clinical Data

This intervention maps to 2 entities in the Healos knowledge graph.

2
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.